SERVING OVERLOOKED PATIENTS
LIVE

Serial Number

97388326

Owner

Azurity Pharmaceuticals, Inc.

Attorney

Douglas R. Wolf

Filing Date

Apr 29, 2022

Add to watchlist:

No watchlists yet
View on USPTO

SERVING OVERLOOKED PATIENTS Trademark

Serial Number: 97388326 • Registration: 8187953

SERVING OVERLOOKED PATIENTS is a trademark filed by Azurity Pharmaceuticals, Inc. on April 29, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Azurity Pharmaceuticals, Inc. (3 trademarks)

8 Cabot Road, Second Floor
Woburn, MA 01801

Entity Type: 03

Trademark Details

Filing Date

April 29, 2022

Registration Date

March 24, 2026

Published for Opposition

February 21, 2023

Goods & Services

Pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicines, topical anti-inflammatory and ultrasound gels, pain and gastrointestinal disorders treatment medicines, and anti-inflammatory, antimicrobial, and antifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorders, colitis, muscle spasm, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; antibiotics; pharmaceutical products for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders having vancomycin, enalapril, lisinopril, and methotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disorders, and for the treatment and prevention of renal, oncological, inflammatory, gastrointestinal, gastroesophageal, and cardio-vascular diseases and disorders

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 24, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 24, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Feb 28, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Feb 28, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Feb 17, 2026 SUPC
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 22, 2025 EXRA
SOU EXTENSION 4 GRANTED
Jul 21, 2025 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 21, 2025 AITU
USE AMENDMENT FILED
Apr 4, 2025 IUAF
SOU TEAS EXTENSION RECEIVED
Apr 4, 2025 EEXT
SOU EXTENSION 4 FILED
Apr 3, 2025 EXT4
TEAS STATEMENT OF USE RECEIVED
Feb 19, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 16, 2024 EXRA
SOU EXTENSION 3 GRANTED
Oct 16, 2024 EX3G
SOU EXTENSION 3 FILED
Oct 16, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 16, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 22, 2024 EXRA
SOU EXTENSION 2 GRANTED
Feb 21, 2024 EX2G
SOU EXTENSION 2 FILED
Feb 21, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 21, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 10, 2023 EXRA
SOU EXTENSION 1 GRANTED
Oct 6, 2023 EX1G
SOU EXTENSION 1 FILED
Oct 6, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 6, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 18, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 21, 2023 NPUB
PUBLISHED FOR OPPOSITION
Feb 21, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 1, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 18, 2023 CNSA
ASSIGNED TO EXAMINER
Jan 10, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 4, 2022 NWOS
NEW APPLICATION ENTERED
May 3, 2022 NWAP